Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01020539 · ClinicalTrials.gov registry record · Phase 1
Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia
A Phase 1 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01020539 is a Phase 1 study that has completed, run by Columbia University. The registered enrollment target is 18 participants.
The verdict
NCT01020539, a Phase 1 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Allogeneic stem cell transplantation (AlloSCT) followed by targeted immune therapy Gemtuzumab Ozogamicin patients with acute myeloid leukemia (AML)/juvenile myelomonocytic leukemia (JMML)/myelodysplastic syndromes (MDS) will be safe and well tolerated.
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Gemtuzumab Ozogamicin
- DRUG GVHD Prophylaxis
- DRUG Anti-Thymocyte Globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2002-09-11 |
| Est. Completion | 2020-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01020539
The ClinicalTrials.gov registry entry for NCT01020539 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT01020539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01020539 about?
NCT01020539 is a clinical study titled "Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia". Allogeneic stem cell transplantation (AlloSCT) followed by targeted immune therapy Gemtuzumab Ozogamicin patients with acute myeloid leukemia (AML)/juvenile myelomonocytic leukemia (JMML)/myelodysplastic syndromes (MDS) will be safe and well tolerated.
What is the current status of trial NCT01020539?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2002-09-11. Estimated completion is 2020-12.
What interventions are being tested in trial NCT01020539?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Gemtuzumab Ozogamicin (DRUG), GVHD Prophylaxis (DRUG), Anti-Thymocyte Globulin (DRUG).
Who is sponsoring clinical trial NCT01020539?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.